Table 3 The discriminatory power (Harrell’s C-index) of the COMPERA 2.0 risk score in the present study and published articles
|  | Patients (n) | Outcome | Harrell’s C-index at baseline | Harrell’s C-index at follow-up | ||
|---|---|---|---|---|---|---|
3-stratum | 4-stratum | 3-stratum | 4-stratum | |||
Hoeper et al. [7] | PAH (1655) | Mortality | Not reported | |||
Boucly et al. [8] | PAH (2879) | Mortality | 0.63 | 0.67 | 0.69 | 0.73 |
Stubbs et al. [9] | Medically-treated CTEPH (128) | Mortality | 0.62 | 0.62 | 0.65 | 0.70 |
The present study (The original version) | BPA-treated CTEPH (175) | Clinical worsening | 0.640 | 0.707 | 0.680 | 0.752 |
The present study (The modified version) | BPA-treated CTEPH (175) | Clinical worsening | 0.685 | 0.737 | 0.624 | 0.724 |
The present study (The hybrid version) | BPA-treated CTEPH (175) | Clinical worsening | 0.714 | 0.767 | 0.705 | 0.748 |